186 related articles for article (PubMed ID: 22406608)
21. Pancreatic vasoactive intestinal polypeptide-secreting tumor: report of a case.
Sheu HW; Chou SY; Yang KC; Kao CR; Yang TL; Shih CC
Taiwan Yi Xue Hui Za Zhi; 1989 Sep; 88(9):931-5. PubMed ID: 2559939
[TBL] [Abstract][Full Text] [Related]
22. Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male.
Abu-Zaid A; Azzam A; Abudan Z; Algouhi A; Almana H; Amin T
Hematol Oncol Stem Cell Ther; 2014 Sep; 7(3):109-15. PubMed ID: 24785507
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide (VIP) secreting tumour of the pancreas.
Sandström R; Alhava EM; Poikolainen E; Puittinen J; Soimakallio S
Ann Chir Gynaecol; 1981; 70(3):124-7. PubMed ID: 6275768
[TBL] [Abstract][Full Text] [Related]
24. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Flückiger A; Schlup P
Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
[TBL] [Abstract][Full Text] [Related]
25. VIPomas: an update in diagnosis and management in a series of 11 patients.
Nikou GC; Toubanakis C; Nikolaou P; Giannatou E; Safioleas M; Mallas E; Polyzos A
Hepatogastroenterology; 2005; 52(64):1259-65. PubMed ID: 16001675
[TBL] [Abstract][Full Text] [Related]
26. Vipoma of the pancreas: observations on the diarhrhea and circulatory disturbances.
Barraclough MA; Bloom SR
Arch Intern Med; 1979 Apr; 139(4):467-71. PubMed ID: 435002
[TBL] [Abstract][Full Text] [Related]
27. Chronic diarrhea of infancy: nonbeta islet cell hyperplasia.
Ghishan FK; Soper RT; Nassif ED; Younoszai MK
Pediatrics; 1979 Jul; 64(1):46-9. PubMed ID: 221877
[TBL] [Abstract][Full Text] [Related]
28. Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity.
Schneider R; Waldmann J; Swaid Z; Ramaswamy A; Fendrich V; Bartsch DK; Schlosser K
Pancreas; 2011 Mar; 40(2):213-21. PubMed ID: 21178652
[TBL] [Abstract][Full Text] [Related]
29. Intractable and dramatic diarrhea in liver transplantation recipient with vasoactive intestinal peptide-producing tumor after split liver transplantation: a case report.
Haiqing W; Jiayin Y; Jian Y; Lunan Y
Transplant Proc; 2015; 47(1):171-3. PubMed ID: 25596962
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.
Nilubol N; Freedman EM; Quezado MM; Patel D; Kebebew E
J Clin Endocrinol Metab; 2016 Oct; 101(10):3564-3567. PubMed ID: 27583474
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
[TBL] [Abstract][Full Text] [Related]
32. Localization of a vasoactive intestinal peptide-producing tumor with selective venous sampling.
Smith FR; Rogers AI
Am J Gastroenterol; 1980 Sep; 74(3):282-4. PubMed ID: 7468568
[TBL] [Abstract][Full Text] [Related]
33. Streptozocin-treated Verner-Morrison Syndrome: plasma vasoactive intestinal peptide and tumor responses.
Gagel RF; Costanza ME; DeLellis RA; Norton RA; Bloom SR; Miller HH; Ucci A; Nathanson L
Arch Intern Med; 1976 Dec; 136(12):1429-35. PubMed ID: 187136
[TBL] [Abstract][Full Text] [Related]
34. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.
Maton PN; O'Dorisio TM; Howe BA; McArthur KE; Howard JM; Cherner JA; Malarkey TB; Collen MJ; Gardner JD; Jensen RT
N Engl J Med; 1985 Jan; 312(1):17-21. PubMed ID: 2856888
[No Abstract] [Full Text] [Related]
35. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
36. Preoperative localization of a vasoactive intestinal peptide-secreting tumor by transhepatic portal venous sampling.
Parkman HP; Malet PF; Ogorek CP; Burke DR; Deveney CW
Am J Gastroenterol; 1988 May; 83(5):559-63. PubMed ID: 2834945
[TBL] [Abstract][Full Text] [Related]
37. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
38. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
39. [WDHA syndrome (watery diarrhea, hypokalemia and achlorhydria) with high VIP contents in the blood and tumor tissue--a case study].
Kawanaka M; Ooiwa N; Toyooka K; Matsuoka T; Mori T; Kakishita E; Nagai K; Sugahara I; Okazora T; Ueki S; Kyo A; Suzuki E; Toyosaka A; Okamoto E; Yamaguchi K; Abe K; Kameya T
Nihon Rinsho; 1978; 36(3):656-62. PubMed ID: 650946
[No Abstract] [Full Text] [Related]
40. [Diagnosis of Verner-Morrison syndrome (VDHA) and its treatment with sandostatin an streptozocitin].
Várkonyi TT; Velösy B; Nagy I; Németh J; Lonovics J
Orv Hetil; 1993 Nov; 134(47):2599-602. PubMed ID: 8247522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
